Drug Profile
Cytisinicline - Achieve Life Sciences
Alternative Names: Cytisine; Cytisine-Achieve-Life-Sciences; Desmoxan; TabexLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Sopharma
- Developer Achieve Life Sciences
- Class 2 ring heterocyclic compounds; Alkaloids; Pyridones; Small molecules; Smoking cessation therapies
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Smoking withdrawal
Most Recent Events
- 02 Apr 2024 Achieve Life Sciences intends to submit supplemental NDA to the US FDA for Smoking withdrawal in the first half of 2025
- 02 Apr 2024 Achieve life sciences plans to request an end-of-Phase 2 meeting with the US FDA to discuss a potential Phase III program in Smoking withdrawal during 2024
- 28 Mar 2024 Achieve Life Sciences has 26 issued patents and 50 pending patent applications for Cytisinicline